Trial reportCancer2013
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.
Trial report in Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00553501 (A Phase II Trial of Extended Induction Epratuzumab), which is not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Trial of Extended Induction Epratuzumab (Anti-CD22 Monoclonal Antibody) (CALGB IND #XXXXX) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
Who cites it
29 citing papers in PubMed, 54 citations in OpenAlex.
- The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials.Cancer medicine · 2019Trial
- Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.Pediatric blood & cancer · 2015Trial
- Eradication of PPMID clone and improvement in cytopenia using cryopreserved autologous haematopoietic stem cells.British journal of haematology · 2026Article
- From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O-GalNAc Glycosylation in Cancer.Chemical reviews · 2026Review
- Advances in Oncohematology Immunotherapy: Monoclonal Antibodies and CAR T-Cell Therapies.Cells · 2026Review
- Cancer-associated alterations in O-GalNAc glycosylation.Glycobiology · 2026Review
- Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma.Blood advances · 2024Article
- A high-throughput lysosome trafficking assay guides ligand selection and elucidates differences in CD22-targeted nanodelivery.Science and technology of advanced materials · 2024Article
- Multi-targeted immunotherapeutics to treat B cell malignancies.Journal of controlled release : official journal of the Controlled Release Society · 2023Review
- Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL.Blood advances · 2023Article
- Chicken-derived CD20 antibodies with potent B-cell depletion activity.British journal of haematology · 2022Article
- Review
- Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma.Blood and lymphatic cancer : targets and therapy · 2021Review
- Role of antibody-based therapy in indolent non-Hodgkin's lymphoma.Leukemia research reports · 2021Review
- Immunotherapy of lymphomas.The Journal of clinical investigation · 2020Review
- Advances in targeted therapy for malignant lymphoma.Signal transduction and targeted therapy · 2020Review
- New Treatment Options in Advanced Stage Follicular Lymphoma.HemaSphere · 2018Review
- Where to start? Upfront therapy for follicular lymphoma in 2018.Hematology. American Society of Hematology. Education Program · 2018Review
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.Nature medicine · 2018Article
- Human CD22 Inhibits Murine B Cell Receptor Activation in a Human CD22 Transgenic Mouse Model.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
Abstract
backgroundRituximab combined with chemotherapy has improved the survival of previously untreated patients with follicular lymphoma (FL). Nevertheless, many patients neither want nor can tolerate chemotherapy, leading to interest in biological approaches. Epratuzumab is a humanized anti-CD22 monoclonal antibody with efficacy in relapsed FL. Because both rituximab and epratuzumab have single-agent activity in FL, the antibody combination was evaluated as initial treatment of patients with FL.
methodsFifty-nine untreated patients with FL received epratuzumab 360 mg/m2 with rituximab 375 mg/m2 weekly for 4 induction doses. This combination was continued as extended induction in weeks 12, 20, 28, and 36. Response assessed by computed tomography was correlated with clinical risk factors, [18F]fluorodeoxyglucose positron emission tomography findings at week 3, Fcγ polymorphisms, immunohistochemical markers, and statin use.
resultsTherapy was well-tolerated, with toxicities similar to expected with rituximab monotherapy. Fifty-two (88.2%) evaluable patients responded, including 25 complete responses (42.4%) and 27 partial responses (45.8%). At 3 years follow-up, 60% of patients remain in remission. Follicular Lymphoma International Prognostic Index (FLIPI) risk strongly predicted progression-free survival (P = .022).
conclusionsThe high response rate and prolonged time to progression observed with this antibody combination are comparable to those observed after standard chemoimmunotherapies and further support the development of biologic, nonchemotherapeutic approaches for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.